Fly News Breaks for December 10, 2019
Dec 10, 2019 | 09:52 EDT
Roth Capital analyst Zegbeh Jallah says GlycoMimetrics' preclinical data presented at ASH was "very exciting," as it showed that resistance to BTK targeting could also be overcome by uproleselan. Although early, Jallah says the data broaden's uproleselan's clinical outlook, which she thinks should begin to attract large pharma attention. The analyst has a Buy rating and $9 price target on the shares.
News For GLYC From the Last 2 Days
There are no results for your query GLYC